Acromegaly is the small but commercially meaningful endocrine market where the next generation of somatostatin-pathway therapeutics is reshaping a category that ran on monthly intramuscular octreotide injections for two decades. Crinetics' Palsonify (paltusotine) — the first once-daily oral SST2 nonpeptide agonist — was approved in the US in late 2025 and won European Commission approval April 27, 2026 across the 27 EU member states plus three EEA countries; Q1 2026 net product revenue was $10.3M with 263 unique prescribers in the first full commercial quarter.
Camurus's Oclaiz (CAM2029), a once-monthly subcutaneous octreotide FluidCrystal depot delivered via prefilled autoinjector, has an FDA PDUFA target action date of June 10, 2026 following an October 2024 Complete Response Letter resolution. The ACROINNOVA Phase 3 program documented approximately five-fold higher bioavailability versus traditional intramuscular octreotide. Pfizer's Somavert and Ipsen's Somatuline remain in the competitive frame.
Stories here cover trial readouts, regulatory milestones, and the broader SST2 competitive landscape. See #palsonify, #paltusotine, #crinetics, and #camurus.
Crinetics Pharmaceuticals reported Q1 2026 results May 7 — total revenue $10.7M (vs $8.5M consensus, +25.7% beat), Palsonify (paltusotine) net product revenue $10.3M in its first full commercial quarter (up from $5.4M in Q4 2025), 263 unique prescribers (up from 125 at year-end), 232 new patient enrollment forms in the quarter, and approximately 70% of patients reimbursed with payer coverage above 60% (target above 75% by Q3). Cash, equivalents, and investments closed at $1.3B. R&D rose 17.6% to $100.1M to fund Phase 3 paltusotine in carcinoid syndrome plus atumelnant Phase 3 programs in congenital adrenal hyperplasia and Cushing's syndrome. Shares rose 4.3% in after-hours trading.
Camurus's Oclaiz (CAM2029) — a once-monthly subcutaneous octreotide FluidCrystal depot delivered via prefilled autoinjector — has an FDA Prescription Drug User Fee Act target action date of June 10, 2026, following an October 2024 Complete Response Letter tied to a third-party manufacturer's cGMP inspection. CAM2029's ACROINNOVA Phase 3 program documented approximately five-fold higher bioavailability versus the currently approved long-acting intramuscular octreotide formulation. The June PDUFA sets up a back-to-back acromegaly decision pair with Crinetics' Palsonify (paltusotine), already approved in the EU on April 27 and reported $10.3M in Q1 US net product revenue (covered above). Both target the same patient population through different routes — once-daily oral nonpeptide vs once-monthly subcutaneous peptide depot.
Crinetics Pharmaceuticals announced April 27 that the European Commission approved Palsonify (paltusotine), a selectively-targeted somatostatin receptor type 2 nonpeptide agonist, as the first once-daily oral therapy for acromegaly in adults across all 27 EU member states plus three EEA countries. The approval rests on two pivotal Phase 3 trials in medical-naïve and previously treated patients, with diarrhea, abdominal pain, and nausea reported as the most common adverse reactions and no serious adverse events in the randomized portion. First launches are planned for Germany and Austria, marking Crinetics' first regulatory approval outside the U.S. and a competitive challenge to injectable somatostatin analogs.